HomeNDC LookupRxCUI directory › RxCUI 351973

Gabapentin 50 MG/ML Oral Solution [Neurontin] — RxCUI 351973

RxNorm drug concept · Semantic branded drug
RxCUI 351973 Semantic branded drug · SBD ● Current RxNorm concept 11 FDA products 11 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI351973
Official nameGabapentin 50 MG/ML Oral Solution [Neurontin]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asNeurontin 50 MG/ML Oral Solution; Neurontin 250 MG in 5 mL Oral Solution; Neurontin 250 MG per 5 ML Oral Solution
FDA products mapped11
Package NDCs mapped11
Reported Medicaid activity (SDUD)4,528 prescriptions · 12 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Gabapentin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Gabapentin is mainly used for two things: managing nerve pain that lingers after a shingles infection (called postherpetic neuralgia) in adults, and helping control partial onset s...
  • This is a really important question. Taking gabapentin together with opioids like morphine, hydrocodone, or oxycodone significantly raises the risk of serious breathing problems —...
  • Can I take gabapentin with my opioid pain medication?
  • The most common ones — especially in the first few weeks — are dizziness, drowsiness, and sometimes loss of balance or coordination. Swelling in the feet or hands is also fairly co...
📖 Read our full Gabapentin guide →

🕸️ Concept Web — How Gabapentin 50 MG/ML Oral Solution [Neurontin] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Gabapentin 50 MG/ML Oral Solution [Neurontin] RxCUI 351973

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Gabapentin 25480
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Neurontin 196498
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Gabapentin Oral Solution 378101
    • Gabapentin Oral Liquid Product 1156680
    • Gabapentin Oral Product 1156681
    • Gabapentin Oral Solution [Neurontin] 364901
    • Neurontin Oral Liquid Product 1182284
    • Neurontin Oral Product 1182285
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Gabapentin 50 MG/ML Oral Solution SCD · 283523
  • Gabapentin 50 MG/ML SCDC · 346365
  • Gabapentin Oral Solution SCDF · 378101
  • Gabapentin Oral Liquid Product SCDG · 1156680
  • Gabapentin Oral Product SCDG · 1156681

Brand-Name Concepts

  • Gabapentin 50 MG/ML [Neurontin] SBDC · 575724
  • Gabapentin Oral Solution [Neurontin] SBDF · 364901
  • Neurontin Oral Liquid Product SBDG · 1182284
  • Neurontin Oral Product SBDG · 1182285
  • Neurontin BN · 196498

📦 FDA Products & Package NDCs

11 products · 11 package NDCs
11 package NDCs map to RxCUI 351973 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00071-0401-24 100 TABLET, FILM COATED in 1 BOTTLE (0071-0401-24) Neurontin Parke-Davis Div of Pfizer Inc 1998-10-09
00071-0803-24 100 CAPSULE in 1 BOTTLE (0071-0803-24) Neurontin Parke-Davis Div of Pfizer Inc 1993-12-30
00071-0805-24 100 CAPSULE in 1 BOTTLE (0071-0805-24) Neurontin Parke-Davis Div of Pfizer Inc 1993-12-30
00071-0806-24 100 CAPSULE in 1 BOTTLE (0071-0806-24) Neurontin Parke-Davis Div of Pfizer Inc 1993-12-30
00071-2012-47 1 BOTTLE, PLASTIC in 1 CARTON (0071-2012-47) / 470 mL in 1... Neurontin Parke-Davis Div of Pfizer Inc 2022-07-12
58151-0281-01 100 CAPSULE in 1 BOTTLE (58151-281-01) Neurontin Viatris Specialty LLC 2025-07-10
58151-0282-01 100 CAPSULE in 1 BOTTLE (58151-282-01) Neurontin Viatris Specialty LLC 2026-04-09
58151-0283-01 100 CAPSULE in 1 BOTTLE (58151-283-01) Neurontin Viatris Specialty LLC 2025-10-01
58151-0284-01 100 TABLET, FILM COATED in 1 BOTTLE (58151-284-01) Neurontin Viatris Specialty LLC 2025-10-01
58151-0285-01 100 TABLET, FILM COATED in 1 BOTTLE (58151-285-01) Neurontin Viatris Specialty LLC 2025-09-19
58151-0290-35 1 BOTTLE in 1 CARTON (58151-290-35) / 470 mL in 1 BOTTLE Neurontin Viatris Specialty LLC 2026-01-14
Observed labelers: Viatris Specialty LLC (6) · Parke-Davis Div of Pfizer Inc (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.